Traws Pharma completes Phase 1 studies for single-dose bird flu drug tivoxavir marboxil

Traws Pharma, Inc.

Phase 1 trial showed safety, tolerability, and PK supporting dosing for H5N1 treatment and prevention.
No significant treatment-related adverse events reported across four dose levels in healthy volunteers.
Preclinical data showed potent inhibition of drug-resistant and highly pathogenic bird flu viruses.
Company plans to use data to guide upcoming regulatory meetings for accelerated development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.